Articles tagged with Flu Vaccines
A two-dose regimen of the H5N1 vaccine induced the highest antibody response after 42 days, with all formulations well-tolerated. However, the level of post-vaccination antibodies needed for protection against the H5 N1 virus remains unknown.
Five Spanish hospitals are participating in a phase III trial for an H5N1 influenza pandemic vaccine, alongside countries such as Germany, Holland, and France. The vaccine uses fractionated viral proteins and an adjuvant to stimulate the immune system, with the goal of improving vaccine production strategies.
A new study by St. Jude Children's Research Hospital has shown a DNA-based vaccine to be highly effective in protecting mice against lethal challenges with the H5N1 avian influenza virus. The vaccine targets two conserved viral proteins and one variable protein, providing complete protection in mice.
A recent study found that an intranasal influenza vaccine was significantly more effective in protecting young children against flu infection than traditional injections. The vaccine, known as CAIV-T, was 55% more effective in reducing influenza-like illness in children.
A new potential vaccine against deadly leishmaniasis has been developed by a research group led by Peter H. Seeberger, combining a virosome delivery system with a synthetic carbohydrate antigen. This innovative approach aims to overcome the limitations of existing vaccines and provide a strong protective action against the disease.
The American College of Physicians emphasizes the need for a comprehensive healthcare response to pandemic influenza, highlighting the critical role of primary care physicians. The organization recommends hands-on clinical training for internists to address public health crises like pandemic influenza.
A large-scale model simulates the spread of a pandemic influenza virus in the US population, exploring the impact of interventions such as vaccination and social distancing. The study finds that stockpiling vaccines and implementing a combination of mitigation strategies could be effective in slowing the spread of the flu.
The Duke study aims to determine whether a modified form of the investigational bird flu vaccine can trigger a strong immune response at lower doses. The seven-month trial will test varying strengths of the H5N1 vaccine, either with or without an aluminum hydroxide adjuvant.
Researchers found that a dose of 90 micrograms per shot was most effective in producing protective antibodies against bird flu. To make the vaccine available to more people, studies are underway to test an adjuvant called alum, which could allow for reduced doses and increased supply.
The H5N1 avian flu vaccine has shown promise in inducing immune responses in healthy adults. Among the 99 participants who received the high-dose vaccine, 54% developed neutralizing antibodies to the vaccine at a serum dilution of 1:40 or greater.
Researchers aim to offer protection to immunocompromised patients without unnecessary vaccination. They will measure T cell and B cell counts to determine which patients benefit from an influenza vaccine, with potential customized treatment recommendations for each group.
A novel vaccine has been shown to be effective in preventing middle ear infections in young children, reducing episodes by about a third. The vaccine targets the bacteria Streptococcus pneumoniae and Haemophilus influenzae, which are leading causes of infection.
A new influenza vaccine using a purified protein from the virus's surface has been developed, showing safety and immunity equal to traditional egg-based vaccines. The vaccine is expected to be produced within 4 weeks and at a cost comparable to traditional methods, providing a significant advantage in fighting potential pandemics.
A Vanderbilt University Medical Center study found that media coverage had a significant impact on pediatric flu vaccination rates nationwide. The study surveyed 256 parents and found that 75% of children with confirmed influenza dates received the vaccine after mid-November 2003, influenced by media attention.
A nationwide study of vaccinating school children against influenza could reduce community transmission and improve vaccine production. The authors suggest a collaboration between academia, government, and industry to conduct such a study.
Researchers genetically engineered an adenovirus to produce a protein from the H5N1 influenza virus, protecting mice from death and weight loss when infected with the virus. The human adenovirus vaccine generated specific T cells that helped clear the virus, offering a viable option for potential pandemic vaccination.
A vaccine developed by University of Pittsburgh Medical Center researchers has shown 100% protection against the avian flu virus in an animal study. The vaccine, which contains a live virus, stimulates several lines of immunity and is expected to have greater therapeutic value than traditional vaccines.
Leading NIAID researchers explore the complex relationship between influenza viruses and the human immune system. They explain how antigenic drift and shift impact vaccine development, highlighting potential vulnerabilities to flu pandemics.
The National Institutes of Health is testing avian influenza vaccines to prevent a possible pandemic. Saint Louis University School of Medicine is conducting a research study using a killed flu virus vaccine in children ages 2-9.
Research by Ann Falsey and Edward Walsh finds that RSV affects elderly and high-risk adults as much as the flu, causing thousands of deaths annually. Hand washing remains ineffective in preventing RSV, despite its proven ability to prevent other infections.
The Fluarix clinical study demonstrated the vaccine's ability to induce protective antibodies, making it a promising tool in bolstering flu vaccine supply. The successful collaboration between academia, industry, and government agencies enabled the rapid development of the vaccine.
Researchers found a 20% increase in pneumonia hospitalization rates for patients aged 65-74 and 75-84 years between 1988-1990 and 2000-2002. The proportion of patients with underlying conditions, such as chronic cardiac disease or diabetes mellitus, increased significantly during this period.
The study found no new or unexpected adverse events, including rare events, reported to VAERS during the first two post-licensure seasons of intranasal flu vaccine use. The researchers identified some potential risks, such as anaphylaxis and asthma exacerbation in individuals with prior asthma history.
Researchers developed a vaccine platform offering protection against pneumocystis, influenza, and other pathogens in immunocompromised individuals. The vaccine uses a specific antigen and CD40L molecule to induce an immune response.
A Johns Hopkins expert recommends making flu vaccination mandatory for healthcare workers to prevent outbreaks. Despite high vaccination rates, nearly 40,000 Americans die from influenza each year, and voluntary programs have shown limited success.
Study identifies chronic conditions, including NNMD, as increasing risk of respiratory failure in children hospitalized with influenza. Children with these conditions are 6-4 times more likely to develop respiratory failure compared to those without.
A team of researchers from the University of Wisconsin-Madison and the University of Tokyo report a new way to generate genetically altered influenza virus. This technique improves upon a previous reverse genetics method by significantly reducing the number of plasmid vectors required, increasing the efficiency of virus production.
A new vaccine study is testing a targeted vaccine against the H5N1 strain of avian influenza, aiming to protect vulnerable populations. Participants will receive three doses of either the vaccine or placebo over six months, with blood samples collected to test for protection.
Pall Corporation's total process management approach can improve vaccine production economics by reducing time, safety risks, and expenses. The use of scalable and disposable technologies enables efficient processing of larger volumes, addressing the need for increased manufacturing capacity in response to pandemic threats.
A DNA vaccine could be a powerful tool to combat the 'bird flu' pandemic, potentially produced in as little as two or three weeks. The technique is largely untested in humans, but it might help slow the spread of the disease if enough conventional vaccines aren't available.
Health officials should consider alternative options due to high flu virus resistance to Tamiflu, a key drug in pandemic preparedness. The discovery raises concerns about the effectiveness of stockpiled doses and may require reevaluation of global strategies.
The study found that drug resistance increased from 0.4% in 1994-1995 to 12.3% in 2003-2004, with 61% of resistant viruses coming from people in Asia. This alarming trend has significant implications for agencies and governments planning to stockpile anti-flu agents.
A study found that less than 8% of nurses and healthcare assistants had annual flu injections, citing lack of knowledge as a major reason. The research also showed that over 51% of respondents took sick leave due to flu-like illnesses during the survey period.
A study found that routine immunisation of infants with the Haemophilus influenzae type b (Hib) vaccine significantly reduced meningitis incidence rates in The Gambia. The researchers hope their findings will encourage other developing countries to adopt Hib vaccination programmes, helping achieve the United Nations' goal of decreasing...
The vaccine industry has declined from 26 companies in 1967 to just five in 2004 due to low market demand and high production costs. Dr. Paul Offit urges legislators to protect vaccines as a vital instrument of public health and recommends financial incentives for manufacturers and healthcare professionals
The US vaccine system is fragile and needs significant improvements, the authors report. Despite record low levels of vaccine-preventable diseases and high immunization rates among children, supply chain issues, cost concerns, and safety threats threaten to derail progress.
A combination vaccine for pneumococcus and meningococcal conjugate showed reduced group C meningococcal immunogenicity compared to separate vaccines. The study, conducted from 2000-2002, found the combination vaccine was safe but not suitable as a replacement for individual vaccines.
Researchers found that short-term stress in mice enhanced their immune reaction to influenza, leading to faster and more successful recovery. This discovery has broad implications for vaccine development, suggesting new strategies could be developed to boost immunity against influenza and potentially other diseases.
A study by Ohio State University researchers found that short bouts of social stress improved the ability of mice to recover from the flu. The stress boosted the production of specialized immune cells called T cells, which fight viruses. This finding may lead to more effective flu vaccines for older adults.
The National Institute of Allergy and Infectious Diseases (NIAID) is conducting a Phase I trial to test the safety and immune response of an inactivated H5N1 avian influenza vaccine. The trial aims to prepare for a potential pandemic, following reports of human cases and suspected transmission.
A new influenza vaccine developed using insect cells can produce a strong immune response in humans and may be scaled up for commercial manufacture. This rapid method uses a purified concentration of hemagglutinin to elicit an immune response against specific flu strains.
Researchers identified a dozen potential facilities worldwide that could manufacture flu vaccines in emergency situations. Cell-based vaccines have the potential to reduce production time and improve flexibility compared to traditional egg culture methods.
A study found that many US children are undervaccinated or have delayed vaccinations in their first 2 years of life. The researchers discovered that on average, children were undervaccinated for 172 days during this period.
Vaccination of healthy children in the US and Canada shows limited efficacy in reducing disease spread, hospitalizations, and complications. The study's findings suggest that immunization of very young children does not support a reduction in mortality and community transmission.
A large-scale study shows that flu vaccination is highly effective in reducing severe end points such as deaths and hospitalizations among high-risk persons of working age. The vaccine benefits people of any age with high-risk medical conditions, not just the elderly.
A recent study found no correlation between increasing flu vaccination coverage in the elderly and declining death rates. The authors suggest that this disconnect may be due to disparities in who is likely to receive vaccination, particularly among those with fragile health. This finding has implications for influenza vaccination policy.
Vaccinating 70% of school children, ages 6 to 18, can reduce community-wide transmission to very low levels. This strategy is more effective than vaccinating only high-risk groups.
At the University of Rochester Medical Center, a team of nurses led by Diane O'Brien and John Treanor developed a system to inoculate over 200 volunteers with an experimental flu vaccine. The study aimed to assess the safety and effectiveness of the vaccine in preventing another flu vaccine shortage.
A vaccine against cervical cancer has been developed by Dutch researcher Laura Bungener. The vaccine induces an immune response to proteins from human papillomavirus (HPV), rendering it harmless and preventing the growth of tumors. Laboratory animals with existing tumors could also be treated with this vaccination.
A NIAID-sponsored clinical trial is enrolling healthy adults to assess the immune response and safety of the Fluarix vaccine, which has been distributed in over 70 countries. The trial will provide valuable information on the vaccine's efficacy before it can be licensed for use in the US.
Researchers found a significant decline in Guillain-Barré syndrome (GBS) reports following influenza vaccination, with annual rates decreasing by 4-fold between 1993-1994 and 2002-2003. A GBS diagnosis was confirmed in 82% of reports, and preceding illness within 4 weeks of vaccination was identified in 24% of cases.
A new study found that computer-assisted standing orders for nurses resulted in significantly better adult immunization rates compared to traditional physician reminders. The study showed that 42% of patients in the standing order group received influenza vaccine, while only 30% in the physician reminder group did so.
A randomized trial found that computerized standing orders for influenza and pneumococcal vaccines significantly increased vaccine administration rates compared to physician reminders. Patients with standing orders received vaccinations 12-24% more often, highlighting the effectiveness of this approach in improving preventive care.
Researchers at Saint Louis University discovered a new flu vaccine solution that uses lower doses in younger adults, which could stretch the nation's vaccine supply by up to 2.5 times. This innovative approach involves administering the vaccine intradermally, between the layers of skin, rather than through a traditional muscle injection.
A study of 26,071 elderly individuals found that annual influenza revaccination was associated with a reduced mortality risk of 24% compared to first-time vaccination. Revaccination after an interruption resulted in a similar mortality risk reduction as seen after the initial vaccination.
Researchers are testing a new flu vaccine grown in insect cell lines, which could reduce production time by one to two months. The study aims to evaluate the effectiveness of the experimental vaccine in healthy adults aged 18-49, with potential benefits including reduced costs and increased dose strength.
The influenza vaccine faces production challenges, with Chiron's manufacturing troubles affecting UK and US supplies. To mitigate this, manufacturers are diversifying their output to ensure vaccination for high-risk groups is maintained.
Researchers are testing the effectiveness of both flu shots and nasal sprays to determine which one provides better protection against influenza. The study aims to gather valuable information for influenza pandemic planning and control annual outbreaks.
The study found that spring-fall flu shots were as effective as traditional fall schedules in protecting toddlers from flu complications. Additionally, the spring-fall schedule allowed children to receive their immunizations earlier and completed their vaccination process faster than those in the standard fall group.
A survey of pediatricians and family physicians found that 80% of pediatricians and 69% of family physicians believed a universal influenza vaccination program for infants would be feasible. The majority also agreed that the vaccine would greatly decrease sickness during the influenza season.